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Objective: To review the evolution of traumatic thoracic aortic injury (TTAI) treatment at a single institution.
Methods: Retrospective analysis of all patients included in an institutional trauma registry and vascular surgery database
who underwent treatment of TTAI between January 1999 and January 2011.
Results: Ninety-one patients (69 males) were treated for TTAI. The mean age was 38.5 years (range, 16-79 years).
Forty-one patients underwent open repair (OR) and 50 thoracic endovascular repair (TEVAR), 37 with thoracic stent
grafts (TSG) alone, 11 with infrarenal aortic extender cuffs (AEC), and two with a combination of TSG and AEC. OR
was performed exclusively until 2004; the last one was performed in January 2007. All TTAIs have since been treated with
TEVAR. The left subclavian artery (LSA) was fully covered in 10 patients (20%) and partially covered in eight patients,
with revascularization in only two cases. The use of AEC and avoidance of LSA coverage increased after 2007. Baseline
characteristics and injury severity scores were similar between groups. The mortality rate was higher in the OR group
(19.5% vs 6.0%; P .06), although it did not reach statistical significance. The overall incidence of morbidities was similar
between the two groups (42% OR vs 50% TEVAR). Two patients developed paraplegia (4.4%) after OR compared with
none after TEVAR. In the TEVAR group, a pseudoaneurysm, an iliac artery thrombosis, and a retroperitoneal hematoma
developed in one patient each. Overall, eight patients (16%) developed stent graft-related complications (SRC), with two
developing early (within 30 days) complications. All complications were related to poor apposition, requiring 10
reinterventions. Four patients underwent open conversions with no mortality. Nine out of 10 SRCs were associated with
the use of thoracic stent graft malapposition. No patient treated with AEC had endoleaks or SRC.
Conclusions: TEVAR for TTAI has superior survival outcomes and has replaced OR. SRC requiring reintervention is
associated with malapposition and the use of TSG. Until TTAI-specific endografts become available, use of AEC may
minimize malapposition and reduce reinterventions. Routine overstenting of the LSA is not necessary and may increase
SRC. (J Vasc Surg 2012;56:74-80.)
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tA traumatic thoracic aortic injury (TTAI) is highly
lethal, with a reported mortality of up to 90% at the scene.1
Patients diagnosed with this condition are often found to
have significant associated head, abdominal, pelvic, and/or
orthopedic injuries. Direct open repair (OR) has been the
mainstay of treatment for TTAI for nearly 50 years. How-
ever, OR is associated with high morbidities and mortali-
ties.2
The advent of endovascular therapy and its widespread
application have led to the treatment of a variety of aortic
diseases, including TTAI. Thoracic endovascular repair
(TEVAR) has rapidly gained popularity due to its minimally
invasive nature and positive short-term outcomes. There-
fore, TEVAR for TTAI has emerged as the preferred mode
of therapy for this challenging problem, even before the
approval by United States Food and Drug Administration.
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74Like any other emerging technology, TEVAR is an
volving therapy that continues to change as clinicians’
TAI management experience accrues. This paper reviews
ore than 10 years of experience and the paradigm change
ith management of TTAI in a single institution.
ETHODS
A retrospective review of a prospectively maintained
rauma registry and vascular surgery database identified 91
atients who underwent either OR (41 patients) or
EVAR (50 patients) for TTAI at the University of Pitts-
urghMedical Center from January 1999 to January 2011.
hose who underwent repair of a pseudoaneurysm from a
emote TTAI were excluded from the analysis. Diagnosis of
TAI was made on the basis of preoperative computed
omography (CT) or contrast angiography findings of a
isrupted aortic wall with contrast extravasation, adjacent
ematoma, pseudoaneurysm, mediastinal hematoma, or
lood in the pleural cavity.
Standard advanced trauma life support protocols were
ollowed to assess and treat the patients in the acute setting.
ife-threatening injuries such as intra-abdominal organ
njury or intracranial hemorrhage were addressed and
reated accordingly. The decision on timing and approach
o repair the aortic injury was made at the discretion of the
reating trauma surgeon in conjunction with a vascular
nd/or a cardiothoracic surgery team.
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Volume 56, Number 1 Celis et al 75After TEVAR, patients underwent CT angiography of
the chest and four-view plain chest radiography at 1month,
6 months, and annually thereafter. Follow-up information
for these patients was obtained from clinical electrical re-
cords with CT scans providing evidence for complications
such as endoleak, migration, or collapse.
Image processing. Vitrea Enterprise Suite (Min-
netonka, Minn) was utilized to determine centerline mea-
surements of the landing zone length preoperatively and
subsequent left subclavian artery (LSA) coverage after stent
deployment. Measurement consensus was reached with a
radiologist prior to blinded collection and interpretation of
data.
Statistical analysis. Nonparametric Wilcoxon rank-
sum test was used for continuous variables and Fisher’s
exact test for categorical data. Probabilities of late survival
and freedom from reintervention were estimated by the
Kaplan-Meier method. All tests were two-sided with signif-
icance set at P  .05. Statistical analyses were performed
using Stata SE 10.0 software (StataCorp, College Station,
Tex).
This study was approved by the University of Pitts-
burgh Institutional Review Board.
RESULTS
Ninety-one patients (69 males) were treated for TTAI.
The mean age was 38.5 years (range, 16-79 years). Forty-
one patients underwent OR and 50 TEVAR. The mean
follow-up period in this study was 24.9 months (OR: 40.4
months, TEVAR: 13.9 months). Baseline characteristics
and comorbidities (hypertension, diabetes, coronary dis-
ease, peripheral arterial disease, and injury severity score)
were similar between the two groups of these relatively
young healthy trauma cohorts (Table I). Themechanism of
injury was blunt traumatic injury in all but one patient, who
sustained an iatrogenic proximal descending thoracic injury
during percutaneous balloon angioplasty for recurrent aor-
tic coarctation syndrome, as described in our earlier re-
port.3
The site of TTAI in the TEVAR group was in the
“classic” location (adjacent to the left subclavian artery) in
48 patients. One patient presented with two separate foci of
Table I. Baseline characteristics
Open repai
Age (mean  SD) 37.6 
Male (%) 31 (75
Injury severity score (interquartile range) 38 (33
Co-morbidities
Hypertension 2 (4.8
Diabetes mellitus 1 (2.4
Coronary artery disease 3 (7.3
Peripheral arterial disease 0
SD, Standard deviation.injury: one in the classic location and another in the distal pescending thoracic aorta (DTA). Another patient pre-
ented with the injury localized in the distal DTA.
The majority of ORs were performed before 2004, and
he last one was in January 2007. The first TEVAR in our
nstitution was performed in 2004. All TTAIs were treated
y TEVAR after January 2007. Thirty-seven patients were
reated with endovascular thoracic stent grafts (TSG) while
1 were treated with only aortic extender cuffs (AEC),
ncluding the sole patient with an isolated distal DTA
esion. An additional two patients received a combination
f TSG and AEC; the AECwas used for proximal extension
n one patient and for a synchronous distal DTA lesion in
ne as mentioned above. The mean number of AEC used
as 3.0 (range, 1-5).
The devices used included the Medtronic Talent Tho-
acic Stent Graft System (Medtronic Vascular, Santa Rosa,
alif; two patients), Cook Zenith TX2 Endovascular Graft,
Cook Inc, Bloomington, Ind; three patients) and the Gore
AG Thoracic Endoprosthesis, (W. L. Gore & Associates
nc, Flagstaff, Ariz; 34 patients), including two patients
ho received the conformable TAG (C-TAG) device as
art of a clinical trial. The AEC used were the Gore Ex-
luder (10 patients) and the AneuRx (Medtronic, Santa
osa, Calif; four) and the Zenith (one patient).
Cerebrospinal fluid (CSF) drainage was utilized in one
atient in the OR group and in none in the TEVAR group.
ll but one patient in the OR group received intraoperative
eparin during the procedure compared with 28 (56%)
atients in the TEVAR group. General anesthesia was used
n all patients except one patient who underwent TEVAR
nder local anesthesia with intravenous sedation.
Technical success rate with TEVAR without the need
or secondary reintervention within 30 days was 96% (48/
0). Two patients required a reintervention 8 and 23 days
fter the initial procedure for endograft collapse.
Operative mortality rate tended to be higher with OR
19.5%) compared with TEVAR (6.0%; P .06), although
tatistical significance was not achieved. There were three
eaths in the TEVAR group. One death occurred on
ostoperative day (POD) 4 after successful placement of
EC for TTAI and open reduction and internal fixation of
ight lower extremity fracture; the cause of death was
Treatment modality
41 Thoracic endovascular repair, n  50 P
39.4  17.50 .643
38 (76) .999
38 (29-43) .426
7 (14%) .178
1 (2%) .999
1 (2%) .324
0 —r, n 
19.7
.6)
-45)
%)
%)
%)ulmonary embolism per autopsy. The second fatality was
o
(
(
m
s
t
d
w
w
a
fi
t
m
s
c
z
c
g
t
o
c
a
s
c
t
s
l
t
m
w
w
d
r
JOURNAL OF VASCULAR SURGERY
July 201276 Celis et alan intraoperative death after deployment of a TSG device in
a 79-year-old female with multiple injuries, including a
pelvic fracture. No autopsy was performed. and the cause of
death was presumed to be hemorrhage. The third death
occurred on POD2 in a patient with a first cervical vertebral
fracture who developed acute respiratory arrest.
The incidence of postoperative complications was over-
all similar between the groups (Table II), including the
incidence of paraplegia (4.4% OR vs 0% TEVAR; P  .2).
Two patients suffered a stroke after TEVAR: an 84-year-old
female with a known traumatic left subarachnoid hema-
toma developed an extensive left cerebellar infarct on POD
1, and a 17-year-old male with multiple injuries, including
bilateral lower extremity long bone fractures, who was
found to have several bilateral hemispheric infarcts on POD
2 likely secondary to fat embolism. The latter recovered
without major neurologic sequelae. Pulmonary complica-
tion rates (68.3% vs 54%; P  .2), length of intensive care
unit stay (11 days vs 8 days; P  .6), and ventilator
dependence time (11 days vs 6 days; P  .2) were compa-
rable between the groups.
Table III. Stent graft-related complications
Pt. Device Symptoms Complica
#1 TAG Chest pain Collapse and PSA
#2 TAG L UE claudication L SCA partial cov
#3 TAG Dizziness, amaurosis fugax L CCA stent impi
#4 TAG None L CCA stent impi
#5 AEC L SCA steal syndrome L SCA coverage
#6 TAG None Graft collapse and
(endoleak I)
#7 TAG None Graft collapse
#8 TAG None Graft collapse
AEC, Aortic extender cuff; HTN, hypertension; L CCA, left common caro
Table II. Postoperative complications
Treatment modality
Complications
Open repair,
n  41 (%)
Thoracic endovascular
repair,
n  50 (%) P
Paraplegia 2 (4.8%) 0 .2
Pulmonary 28 (68.3%) 27 (54%) .20
Cardiac 2 (4.8%) 5 (10%) .45
Renal 6 (14.6%) 6 (12%) .76
Cerebrovascular
accident
0 1 (2%) .99
Access site NA 3 (6%) .25
NA, Not available.recorded; PSA, pseudoaneurysm; TAG, Gore TAG Thoracic Endoprosthesis; TEV
operation; TSG, thoracic stent graft.Ten stent graft-related complications (SRCs) devel-
ped in eight patients (16%): early (within 30 days) in two
4%) patients and late (after 30 days) in six (12%) patients
Table III). Nine out of 10 SRCs were associated with TSG
alapposition. One patient treated with AEC developed
ubclavian steal syndrome, which required a left subclavian
o carotid transposition 23 months after the initial proce-
ure. No endoleak, hemodynamic compromise, or collapse
as associated with the use of AEC. The two early SRCs
ere asymptomatic graft collapses identified in a postoper-
tive angiogram during removal of an inferior vena cava
lter and a routine postoperative CT angiography, respec-
ively. All the late SRCs were symptomatic and related to
alapposition, leading to nine reinterventions.
In four cases (8%), a secondary TEVAR was needed for
tent graft collapse. The average oversizing for those with
ollapse was 16% (range, 13%-18%). The proximal landing
one was in zone 2 and zone 3 in two patients each. Open
onversion was ultimately required in two patients for stent
raft-esophageal fistula and physiological aortic coarcta-
ion, respectively. An additional two patients underwent an
pen conversion for hemodynamic obstruction of the left
ommon carotid artery. One patient presented 28 months
fter the initial TEVAR with dizziness and amaurosis fugax
econdary to hemodynamic obstruction of the left common
arotid artery by the TAG device protruding into the
ransverse arch. The second patient was noted to have
imilar radiologic findings without symptoms in a surveil-
ance CT obtained 28 months after the initial repair; al-
hough he was asymptomatic, the patient was recom-
ended to undergo open conversion, lest collapse occur
ith catastrophic complications. No mortality occurred
ith open conversions. These cases of collapse and hemo-
ynamic compromise requiring open conversion have been
eported in detail.4-6
omplication 1
Time Rx
oleak I) 5 months Redo TEVAR with L SCA coverage
22 months L SCA stent placement
ent 28 months Open repair: TAG excision, distal
aortic arch replacement and
LSCA revascularization
ent 28.5 months Open repair: TAG excision, distal
aortic arch replacement and
LSCA revascularization
23 months L subclavian transposition
1.3 months TEVAR TSG
23 days Redo TEVAR
8 days Redo TEVAR
tery; L SCA, left subclavian artery; L UE, left upper extremity; NR, noneC
tion
(end
erage
ngem
ngem
PSA
tid ar
AR, thoracic endovascular repair; Time, time of complication from initial
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Volume 56, Number 1 Celis et al 77Delayed LSA revascularization was required in two
patients. As stated above, one patient underwent an LSA
transposition 23 months after TEVAR with AEC and LSA
coverage due to subclavian steal syndrome. The second
patient was treated with an LSA stent placement 22months
after partial LSA coverage with TAG due to left upper
extremity claudication.
An increased use of AEC was noted since 2007 espe-
cially for patients with short proximal landing zones. A
short landing zone (2 cm) from the LSA to tear site was
identified in 40 of 50 (80%) patients (one patient who had
an LSA turn-down procedure for congenital aortic coarc-
tation syndrome in early childhood was excluded from
analysis). The average proximal landing zone was 16.2 mm
by centerline measurement for the entire group. The LSA
was partially (50%) covered in eight patients and fully
covered in another 10. Of the 12 patients treated with
AECs (either AEC alone or with proximal extension with
an AEC), only three patients had the proximal landing zone
in zone 2, with seven in zone 3 and two in zone 4. By
comparison, in the 38 TSG patients, 22 patients (58%) had
the stent graft deployed in zone 2 and the remainder in
zone 3. Revascularization of the LSA was needed in two of
10 patients (20%) in this subgroup as noted above. The
remaining 32 patients had a TEVAR without coverage of
the LSA. Overall, 12 patients were treated with AEC either
by AEC alone or for proximal extension. Proximal deploy-
ment in zone 2 with either partial or complete coverage of
the LSA was associated with a higher incidence of SRC
(28%, 5/18 patients) than in zone 3 or 4 (6%, 2/31
patients; odds ratio [OR], 5.59; 28% vs 6%; 95% confidence
interval [CI], 0.95-32.6), but this was statistically nonsig-
nificant. LSA coverage was not associated with increased
need for reintervention (OR, 3.9; 26.7% vs 8.6%; 95% CI,
0.5-29.8; P  .2).
There were three access site-related complications in
the TEVAR group. One episode of external iliac artery
Table III. Continued.
Comp
Symptoms Complication
Chest pain and hematemesis Aorta-esophaegeal fistula
NR NR
NR NR
NR NR
NR NR
Proximal HTN Graft collapse and phys. coarcta
NR NR
NR NRhrombosis was detected at the time of the common fem-
ral artery closure; this was successfully managed by embo-
ectomy. A retroperitoneal bleeding due to a closure device
ailure was managed by open repair. Of 15 patients who
nderwent TEVAR via percutaneous approach, one patient
eveloped a common femoral artery pseudoaneurysm 1
eek later which was successfully treated with thrombin
njection.
ISCUSSION
This study shows that TEVAR for TTAI provides su-
erior survival outcomes compared with open repair. It also
llustrates the evolution of the TEVAR technique for TTAI
rom liberal coverage of LSA into rather selective LSA even
ith compromised (short) proximal landing zones, and the
se of AECs for better graft-aortic wall apposition with
mproved outcomes.
The perceived benefits of TEVAR have led to rather
idespread adoption of this technology for the treatment
f TTAI. The comparison of the American Association for
he Study of Trauma studies (AAST12 and AAST27)
howed that the proportion of patients treated with
EVAR for TTAI increased to 65% over a 10-year period
rom 1997 to 2007. This paradigm shift is justified by
mproved early outcomes with TEVAR. It also showed
ignificantly decreased mortality (22.0% vs 13.0%) and
araplegia (8.7% vs 1.6%) rates and attributed these find-
ngs to the widespread use of TEVAR in the AAST2.8
urthermore, multiple meta-analyses have reported supe-
ior short-term advantages with reduced mortality and
araplegia rates after TEVAR as compared with OR.9-11
his led to the recent recommendation of preferential
ndovascular treatment of TTAI over OR in the recently
ssued Clinical Practice Guidelines of the Society for
ascular Surgery, albeit based on very low quality evi-
ence.12-14 It is expected that this paradigm shift will
ersist and be adopted even at a greater scale, although
on 2
Time Rx
6 months Open repair: TAG excision, distal aortic arch
replacement and L SCA revascularization
NR NR
NR NR
NR NR
NR NR
Open repair: TAG excision, distal aortic arch
replacement and L SCA revascularization
NR NR
NR NRlicati
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TEVAR.14
In the present series, a survival benefit was observed
with TEVAR and the incidence rates of paraplegia were not
significantly different. This is consistent with the results of
the more recent AAST2 study, which reported a paraplegia
rate of 2.9% with OR compared with 0.8% with TEVAR
(P .28). Other single-institution comparison studies have
documented similar findings. Mildgley et al reported no
cases of paraplegia after TEVAR compared with one fol-
lowing open repair.13 In a more recent series, Patel et al
observed no significant difference in the incidences of spinal
cord ischemia between open and endovascular repair of
TTAI (2% open repair vs 0%TEVAR).14 This may be due to
improvement in surgical techniques with adjunctive proce-
dures, as well as delayed repair that allows better resuscita-
tion and a more controlled environment.8 That all patients
in the current study were treated by TEVAR since 2007
reflects the national paradigm shift.
The issues concerning the LSA have undergone a full
circle of evolution. The prevalent tenet in the early experi-
ence of TEVAR for TTAI was liberal coverage of LSA to
secure an adequate proximal sealing zone of 2 cm. This
was borne out of recommendations for TEVAR for degen-
erative thoracic aortic aneurysmal disease and the concern
for deployment of stent graft in the “injured” aorta. Pro-
phylactic revascularization of the LSA was routinely per-
formed in the early days of TEVAR, but now expectant
management is recommended in acute settings.15 In the
current study, the majority of patients had a 2 cm proxi-
mal landing zone; the average landing zone was 16.2 mm,
as other investigators have shown.16 The need for LSA
revascularization after complete coverage of the vessel in
the present series (22.2%) is comparable with the literature
pertaining to TEVAR for acute and chronic thoracic aortic
pathology17 (23% complication rate without vs 3% with
LSA revascularization) and for TTAI18,19; partial or com-
plete coverage of the LSA (secondary effects of trying to
gain 2 cm proximal landing zone) tended to have a higher
incidence of SRC compared with no coverage of the vessel
(27% vs 9%). While at least 2 cm of landing zone may be
required in the atherosclerotic aorta, such does not appear
to be necessary in the treatment of TTAI. Otherwise
healthy injured aorta seems to heal well with 2 cm of
coverage once the injured segment is effectively excluded
from circulation. Thus, authors try to avoid covering the
LSA.
Another important SRC is malapposition of the stent
graft onto the aortic arch. This is more likely to occur after
TEVAR for TTAI than for aneurysmal diseases due to the
combination of tight aortic arch angulation, smaller aortic
diameters of young trauma victims, and the lack of TTAI-
specific thoracic endografts.3,5,16 While most are innocu-
ous, it may portend development of a myriad of complica-
tions such as device collapse, physiological aortic
coarctation, or impingement of the great vessels resulting
in hemodynamic disturbances.4-6 aOne way to avert the SRC is use of AEC. Several studies
ave reported its safety and efficacy with good short-term
esults in the treatment of TTAI.20-22 The small diameter
nd shorter length of these devices allow better fit into the
maller and highly angulated aorta. It is noteworthy that
hile all three AECs deployed in zone 2 had some degree of
alapposition causing bird beak appearance, the overall
ength of stent protruding into the aorta was shorter with
EC when compared with TSG, and that no SRC was
bserved in these patients. The benefits of AEC appear to
e multifaceted. The smaller diameter provides better size
atching and the shorter length may reduce protrusion
nto the aortic lumen and consequent physiological coarc-
ation or malperfusion of the common carotid and/or the
SA.4,5 Furthermore, an increased radial force in the AEC
verlap area may also mitigate a cantilever effect, which
ortends the development of either migration or collapse.
t should be noted that not all stent graft collapse occurred
n patients with the proximal leading edge of the stent graft
n zone 2; of four collapses, two occurred in patients with
he proximal landing zone in 2. First used in January of
004 at our institution, we have increasingly utilized AEC
ince 2007 after witnessing several malapposition-related
omplications. While we have not established a treatment
lgorithm at our institution, we discourage coverage of the
SA even when the proximal landing zone is2 cm; use of
EC vs TSG is left up to the surgeon’s experience and
iscernment. This may also help reduce the incidence of
pinal cord ischemia; although it occurs rather infrequently,
very effort should be made to avoid this devastating com-
lication.
Recently, newer generation devices with smaller diam-
ters and lengths have been used off-label to treat TTAI.
owever, it should be pointed out that the smallest aortic
iameter treatable by these devices ranges from 22 mm to
4 mm, still significantly larger than the mean aortic arch
iameter of trauma victims, 19.3 mm.23 It remains to be
een how these newer generation devices will perform in
he treatment of TTAI.
The use of AEC may be accompanied, however, by an
ncreased risk of endoleak. Rosenthal et al, in a series of
TAI repaired exclusively with AECs, noted two (6.5%)
ases of proximal Type I endoleaks among 31 patients; of
ote, the aortic length from the subclavian artery to the
njury averaged 2.5 cm (range, 1.5-4 cm).21 The results in
he current series indicate that with the use of AEC, exten-
ion into zone 2 can be avoided even in patients with2 cm
roximal landing zone without an attendant increase in
ndoleak or failure to exclude the TTAI. No endoleak,
ompromised proximal sealing, or reperfusion of the pseu-
oaneurysm occurred with the use of AEC in this series.
ather, the majority of SRCs occurred with the use of
horacic stent grafts. Furthermore, more SRCs requiring
econdary interventions occurred in patients with deploy-
ent in zone 2.
One of the limitations for the use of AEC is inadequate
evice length for accessing the thoracic aorta via a femoral
pproach. In such as setting, an iliac conduit may be used to
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Volume 56, Number 1 Celis et al 79reach the aorta.20,21 In the present series, one patient
required an iliac conduit, and another patient had an infra-
renal aortic access at the time of exploratory celiotomy. In
the remaining patients, AEC was successfully deployed via
transfemoral approach. Avoiding the sheath and using the
bareback technique allows extra length that may obviate
the need for iliac conduit.
Other potential advantages of TEVAR over OR for
TTAI include the avoidance of general anesthesia, systemic
heparinization, and percutaneous femoral artery access.
The benefit of avoiding general anesthesia with TEVAR
was not observed in this series since all but one patient
received general anesthesia for TEVAR. A significant num-
ber of patients in this group (42%) underwent general
anesthesia for concomitant surgical procedures for other
injuries. The use of systemic heparinization, however, was
reduced with TEVAR (56%). It is not clear if this translated
to any clinical benefits of reduced incidence of blood prod-
uct transfusion requirements or not. The incidences of
bleeding complication that required reoperation between
the groups did not differ. CSF drain was not employed at all
in the TEVAR group.
The traditional approach to TEVAR involved groin
incisions under general or epidural anesthesia. This ap-
proach required exposure of the common femoral artery
with proximal and distal control for the introduction of a
large bore sheath or as access site for a bareback technique.
As technology improves and moves toward less invasive
procedures, percutaneous access is the logical next step.
Multiple reports address the safety and efficacy of this
approach, reporting decreased incidence of wound compli-
cations, nerve injuries, and expeditious recovery.20,24 Our
access site complication rate (6.1%) compares favorably
with that previously reported for the same population
(8.3%).25
This study is limited by several factors. This is a retro-
spective study with a selection bias in regard to the choice of
therapeutic approach, and as such, it precludes direct com-
parison of the two therapeutic modalities. Follow-up is
limited due to the intrinsic trauma population characteris-
tics. The number of patients is relatively small, increasing
the risk for Type II error. The results from the TEVAR
cohorts may not be applicable to other commercially avail-
able devices, as the data from this series are primarily
relevant to the TAG device.
CONCLUSIONS
TEVAR for TTAI confers superior survival outcomes
and has replaced OR as the primary treatment of choice.
The usage of AEC and avoidance of LSA coverage are
effective means of treating TTAI and seem to have lower
complication rates than use of TSG. Routine coverage of
the LSA for over-stenting is not necessary and may increase
SRC. Until TTAI-specific endografts become more widely
available, the use of AEC may minimize malapposition and
reduce secondary reinterventions.The authors gratefully acknowledge Thomas G. Glea-
on, MD, in the Division of Cardiothoracic Surgery and
ou Alarcon, MD, and Andrew B. Peitzman, MD, in the
ivision of Trauma Surgery for their contribution to this
rticle.
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